Source 1review2018Frontiers in Pediatrics
Toolkit/anti-sense oligonucleotides
anti-sense oligonucleotides
Also known as: antisense oligonucleotides, ASOs
Taxonomy: Mechanism Branch / Component. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Suppression of NF-κβ can be achieved through many modalities including anti-sense oligonucleotides (ASOs), siRNA (small interfering RNA), factors regulating NF-κβ, and microbes.
Usefulness & Problems
Why this is useful
ASOs are presented as one modality for suppressing NF-κβ in IBD. In this review context, they are framed as a route to attenuate NF-κβ-induced inflammation.; attenuating NF-κβ-induced inflammation; targeted therapeutic intervention against NF-κβ signaling in IBD
Source:
ASOs are presented as one modality for suppressing NF-κβ in IBD. In this review context, they are framed as a route to attenuate NF-κβ-induced inflammation.
Source:
attenuating NF-κβ-induced inflammation
Source:
targeted therapeutic intervention against NF-κβ signaling in IBD
Problem solved
The modality is proposed to help reduce uncontrolled NF-κβ signaling that contributes to chronic gut inflammation in IBD.; providing a modality to suppress NF-κβ activity
Source:
The modality is proposed to help reduce uncontrolled NF-κβ signaling that contributes to chronic gut inflammation in IBD.
Source:
providing a modality to suppress NF-κβ activity
Problem links
providing a modality to suppress NF-κβ activity
LiteratureThe modality is proposed to help reduce uncontrolled NF-κβ signaling that contributes to chronic gut inflammation in IBD.
Source:
The modality is proposed to help reduce uncontrolled NF-κβ signaling that contributes to chronic gut inflammation in IBD.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Component: A low-level RNA part used inside a larger architecture that realizes a mechanism.
Mechanisms
antisense-mediated suppressionTechniques
No technique tags yet.
Target processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: actuator
A practical ASO approach would require a defined nucleic-acid target in the NF-κβ pathway and a delivery strategy, although the abstract does not specify either.; requires a defined antisense target within the NF-κβ pathway; therapeutic use would require delivery into relevant gut or immune compartments, not specified in the abstract
The abstract does not show that ASOs alone address upstream causes such as dysbiosis or all regulatory defects affecting NF-κβ.; the abstract does not specify sequence targets, delivery strategy, or comparative efficacy
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Suppression of NF-κβ can be achieved through modalities including ASOs, siRNA, factors regulating NF-κβ, and microbes.
Approval Evidence
1 source1 linked approval claimfirst-pass slug anti-sense-oligonucleotides
Suppression of NF-κβ can be achieved through many modalities including anti-sense oligonucleotides (ASOs), siRNA (small interfering RNA), factors regulating NF-κβ, and microbes.
Source:
therapeutic strategysupports
Suppression of NF-κβ can be achieved through modalities including ASOs, siRNA, factors regulating NF-κβ, and microbes.
Source:
Comparisons
Source-stated alternatives
The abstract names siRNA, factors regulating NF-κβ, and microbes as alternative suppression modalities.
Source:
The abstract names siRNA, factors regulating NF-κβ, and microbes as alternative suppression modalities.
Source-backed strengths
explicitly named as a therapeutic suppression modality in the review abstract
Source:
explicitly named as a therapeutic suppression modality in the review abstract
Compared with small interfering RNA
The abstract names siRNA, factors regulating NF-κβ, and microbes as alternative suppression modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly named as a therapeutic suppression modality in the review abstract.
Relative tradeoffs: the abstract does not specify sequence targets, delivery strategy, or comparative efficacy.
Source:
The abstract names siRNA, factors regulating NF-κβ, and microbes as alternative suppression modalities.
Ranked Citations
- 1.